Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
Arla Foods Ingredients Targets GLP-1 Companion Nutrition at Vitafoods Europe
GlobeNewswire, Inc.
COPENHAGEN, Denmark, April 14, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients has developed high-protein, nutrient-dense application concepts for users of GLP-1 anti-obesity medications, which it will showcase at Vitafoods Europe (5th-7th May...
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
GlobeNewswire, Inc.
Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 -...
Clinical Study Provides Evidence for the Use of Arla Foods Ingredients’ Lacprodan® IF-3070 in Infant Formula
GlobeNewswire, Inc.
COPENHAGEN, Denmark, March 22, 2026 (GLOBE NEWSWIRE) -- A clinical study published in Nutrients has shown that infant formula containing Arla Foods Ingredients’ Lacprodan® IF-3070 was well tolerated in infants, with growth and development...
Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer
EIN Presswire
Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, UNITED STATES, March 17, 2026 /EINPresswire.com/ -- Pharmacosmos today announced the initiation of a phase III, randomised,...
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
GlobeNewswire, Inc.
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Simplified listing structure...
ESO Acquires d2i, Accelerating Emergency Intelligence to Drive Performance and Improve Outcomes across Fire, EMS and Health Systems
GlobeNewswire, Inc.
AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- ESO Solutions, Inc. (“ESO”), a leading data services and software company serving fire departments, EMS, hospitals and government agencies, today announced it has acquired d2i, a healthcare...
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
GlobeNewswire, Inc.
Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a...
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
GlobeNewswire, Inc.
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Dutch Nonprofit Files Lawsuit Against Meta for Child Mental Health Risks
MENAFN
(MENAFN) A Dutch nonprofit has filed a lawsuit against Meta in Denmark on behalf of parents and children, claiming that the company’s platforms cause psychological harm to minors.
AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance
GlobeNewswire, Inc.
HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and...
Resolutions from Zealand Pharma's Annual General Meeting 2026
GlobeNewswire, Inc.
Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology...
Older Adults Health Supplements Market to Reach USD 351.1 Billion by 2036 Amid Rising Global Ageing Demand
EIN Presswire
Older Adults Health Supplements Market Growth is driven by rising longevity, preventive healthcare adoption, and expanding digital retail channels DELAWARE, NJ, UNITED STATES, March 26, 2026 /EINPresswire.com/ -- The global older adults’ health...
VIVUS Reinforces QSIVA®’s Clinical Efficacy and Safety in Obesity Management
GlobeNewswire, Inc.
— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a...
Hospitals Electronic Health Records Turn Data Into Better Decisions, Approaching $28.94 Billion by 2035
GlobeNewswire, Inc.
Ottawa, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The global hospital electronic health records market size is calculated at USD 19.39 billion in 2026 and is expected to reach around USD 28.94 billion by 2035, growing at a CAGR of 4.55% for the forecasted...
Groundbreaking Danish research project launches to cure Parkinson’s disease
GlobeNewswire, Inc.
A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease.
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation
GlobeNewswire, Inc.
Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area,...
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
GlobeNewswire, Inc.
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer immunotherapies, and their...
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
GlobeNewswire, Inc.
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
GlobeNewswire, Inc.
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments and is...
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
GlobeNewswire, Inc.
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial PK/PD...
Sign up for:
Healthcare Times Denmark
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.